Akero Therapeutics
AKRO
AKRO was delisted on the 8th of December, 2025.
113 hedge funds and large institutions have $329M invested in Akero Therapeutics in 2022 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 40 increasing their positions, 29 reducing their positions, and 10 closing their positions.
120% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 10
61% more call options, than puts
Call options by funds: $111K | Put options by funds: $69K
38% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 29
10% more funds holding
Funds holding: 103 → 113 (+10)
4.35% more ownership
Funds ownership: 100.52% → 104.87% (+4.4%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
34% less capital invested
Capital invested by funds: $499M → $329M (-$170M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$10.5M |
| 2 |
Goldman Sachs
New York
|
+$8.04M |
| 3 |
Millennium Management
New York
|
+$4.75M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.72M |
| 5 |
YCM
Yiheng Capital Management
San Francisco,
California
|
+$3.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$16M |
| 2 |
VVM
Versant Venture Management
San Francisco,
California
|
-$8.77M |
| 3 |
State Street
Boston,
Massachusetts
|
-$7.78M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$3.13M |
| 5 |
Rafferty Asset Management
New York
|
-$957K |
AKRO Hedge Fund Activity: Q2 2022 in Review
113 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Akero Therapeutics (AKRO) for Q2 2022, worth a combined $329M — down 34% from $499M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new AKRO positions and 10 closed out — a net gain of 12 holders — while 40 added to existing stakes and 29 trimmed.
The largest buyer was Marshall Wace, opening a new position worth an estimated $10.5M. The largest seller was Wellington Management Group, cutting an estimated $16M.
- 113 institutional investors held Akero Therapeutics (AKRO) as of Q2 2022, up from 103 in Q1 2022.
- Funds reported $329M of Akero Therapeutics stock for Q2 2022, down 34% quarter-over-quarter.
- 22 funds opened new Akero Therapeutics positions in Q2 2022 and 10 closed out, a net change of +12 holders.
- The largest Akero Therapeutics buyer in Q2 2022 was Marshall Wace, an estimated $10.5M added.
- The largest Akero Therapeutics seller in Q2 2022 was Wellington Management Group, an estimated $16M sold.
Based on aggregated 13F filings for Q2 2022.